2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 313

Do Musculoskeletal Ultrasound and Magnetic Resonance Imaging Identify Synovitis and Tenosynovitis at the Same Joints and Tendons? – a Comparative Study in Patients Presenting with Early Arthritis and Clinically Suspect Arthralgia
Abstract Number: 314

Development and Preliminary Validation of an Omeract Magnetic Resonance Imaging (MRI) Scoring System for Ankle Enthesitis in Spondyloarthritis
Abstract Number: 315

Assessing the Value of Whole Body Magnetic Resonance Imaging As to Clinical Examination to Predict Remission and Relapse in Early Peripheral Spondyloarthritis
Abstract Number: 316

Eligibility Rates in Axial Spondyloarthritis Clinical Trials Based on Imaging Criteria
Abstract Number: 317

Imaging Biomarker Based Patient Stratification: Initial Data and Validation in Four Most Common Knee Arthritic Diseases
Abstract Number: 318

Inflammatory Findings Detected By MRI at Entheseal Sites in the Pelvic Girdle of Patients with Polymyalgia Rheumatica Have Potential for a Diagnostic Test
Abstract Number: 319

Patterns of Muscle Oedema, Atrophy and Fatty Replacement in the Idiopathic Inflammatory Myopathies: A Single-Centre Retrospective Review of Magnetic Resonance Imaging Data
Abstract Number: 320

Development of a Magnetic Resonance Imaging Atlas for the Classification of Osteoarthritis of the First Metatarsophalangeal Joint
Abstract Number: 321

In Rheumatoid Arthritis All Disease Activities Are Not Created Equal
Abstract Number: 322

Swollen Joint Count Vs. RAPID3: Why a Discrepancy in Remission State?
Abstract Number: 323

Impact of Gains in Rheumatoid Arthritis Disease Activity Documentation on Outcomes over Time
Abstract Number: 324

Three Health It Interventions Increased Documentation of RA Disease Activity Scores in an Academic Rheumatology Clinic: Results from an Interrupted Time Series Study
Abstract Number: 325

A Comparison of RADAI5 and RAPID3 Disease Measures
Abstract Number: 326

Implementation of a Treat-to-Target Quality Improvement Program for Rheumatoid Arthritis Management Using Real-Time Patient Reported Outcome Measures
Abstract Number: 327

The Patient Global Assessment and Common Composite Disease Activity Measures Vary Minimally When Patients Reflect on Their Arthritis or Their Global Health: Results from the Canadian Early Arthritis Cohort Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].